The global antipsychotic
drugs market is expected to reach USD 14.4 billion by 2025,
according to a new report by Grand View Research, Inc. The continuous
development of better next-generation products to overcome adverse effects and
unwanted reactions of existing products is creating demand for newer products.
This factor is anticipated to propel the market.
Rapid growth of antipsychotics can be attributed to
the rising prevalence of psychosis and other mental disorders. Governments are
focused on creating awareness regarding mental health and psychological
illnesses, which is further anticipated to drive the demand for antipsychotics.
Government bodies in collaboration with major players conduct social programs
to break the stigma related to psychotic disorders that exists in the society.
Adverse effects of antipsychotics, such as insomnia,
dry mouth, drowsiness, and blurred vision, are expected to affect the growth by
decreasing the level of acceptance in patients. In addition, the possibility of
dependency, habit formation, or addiction is affecting the adoption of these
drugs.
Established brands such as, Zyprexa lost patent
protection in October 2011, followed by Seroquel and Risperdal in 2012, which
hampers the market growth for these drugs. Also, the entry of generic versions
of these products slowed the growth of the already existing brands.
Browse full research report on Antipsychotic Drugs Market: https://www.grandviewresearch.com/industry-analysis/antipsychotic-drugs-market
Further
Key Findings From the Study Suggest:
- The growing prevalence of mental disorders, increased investments
on R&D, and rising awareness regarding these conditions are augmenting
the growth of the market.
- The first-generation of antipsychotics have serious adverse effects
and are very rarely used, hence they hold negligible share in the market.
- The second-generation segment of drugs accounted for the largest
share in 2015 and are anticipated to further expand during the forecast
period despite the adverse effects
- As of January 2016, the third-generation segment has only one
approved product, Abilify. It has negligible adverse effects and is
expected to be the fastest growing segment over the forecast period
- In 2015, North America dominated the global space with the largest
revenue share owing to rising prevalence of mental illnesses
- Asia Pacific is expected to emerge as the fastest growing region
during the forecast period, mainly due to growing social awareness
regarding mental disorders and improving access to treatment
- Some of the major players in this market are Johnson & Johnson;
Pfizer, Inc.; Eli Lilly & Co.; and Bristol-Myers Squibb
Browse more reports of this category
by Grand View Research: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand
View Research has segmented the antipsychotic drugs market by drug class,
application, and region:
Antipsychotics
Drug Class Outlook (Revenue, USD Million; 2014 - 2025)
- First
Generation
- Second
Generation
- Third
Generation
Antipsychotics
Application Outlook (Revenue, USD Million; 2014 - 2025)
- Schizophrenia
- Bipolar
disorder
- Unipolar
depression
- Dementia
- Others
Antipsychotics
Regional Outlook (Revenue, USD Million; 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
About Grand View
Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment